Head and neck: Posterior uveal melanoma

Identity

Phylum	Head and Neck:Eye:Intraocular:Choroidal and RPE lesions:Post uveal melanoma
Other names	Ocular melanoma

Classification

Note

Uveal melanoma is a tumor of the adult age, which derives from the pigmented uveal tract of the eye, comprising iris, ciliary body and choroid. The most common site of origin is the choroid (80-90% of cases), while tumors arising from the ciliary body (5-12%) and iris (3-8%) are extremely rare. Choroid melanomas are the commonest type (60-70%), while iris melanomas are particularly rare (5-8%).

Clinics and Pathology

Embryonic origin	Neuroectodermal cell lineage.
Etiology	Despite a large amount of epidemiological and molecular studies, the etiology of uveal melanoma remains largely obscure. Unlike cutaneous melanoma, which shows familial aggregation in at least 10% of cases and for which two major responsible genes have been identified to date, uveal melanoma is rarely caused by inherited mutations. In fact, less than 2% of uveal melanoma are associated to germline mutations in BRCA2 and CDKN2A genes. Moreover, the influence of environmental factors, especially exposure to sunlight, is still debated. However, it is well known that uveal melanomas are more common in older patients, particularly if of Caucasian ancestry and with blue/grey eyes. Therefore, to date, a potential role of sunlight exposure in the pathogenesis of uveal melanoma could not be excluded.
Epidemiology	Uveal melanoma is the most common human intraocular tumor in adult patients, although it represents only 3% of all melanomas. Overall annual incidence is 5-7 cases per million/year. In particular, the mean age-adjusted incidence of uveal melanoma is 4.3 per million/year in the United States, where this value remained stable in a 25-year period. Conversely, in Sweden, the incidence of uveal melanoma declined from 11.7 to 8.4 per million males/year and from 10.3 to 8.7 per million females/year over a 4-decade period. There is no evidence of sex predominance. Likely cutaneous melanoma, the incidence is higher amongst fair skinned pale eyed individuals.
Clinics	Obscured vision symptons of a retinal detachment. Uveal melanoma is a tumor of the adult age. The mean age at diagnosis is about 55 years. The early progression of uveal melanoma is usually asymptomatic. In fact, nearly half of the patients are free of symptoms at the time of the diagnosis. The most common reported abnormalities are blurred vision, photopsia and visual field loss. Additional features are inflamed and painful eye, cataract and glaucoma. Occasionally, uveal melanoma may be externally visible and mimick iris cysts. The diagnosis is established by the ophthalmologist. Binocular indirect ophthalmoscopy and documentation by colour and digital photography greatly enhanced the diagnosis of uveal melanoma. Indocyanine green angiography represents a diagnostic support in defining tumor margins. Ocular ultrasonography is useful for measuring tumor dimensions when planning treatment.
Pathology	Uveal melanoma may develop from melanocytoma, ocular melanocytosis or choroidal nevus. Histologically, six different types of uveal melanoma can be identified: (i) spindle A, (ii) spindle B, (iii) fascicular, (iv) mixed spindle and epithelioid, (v) necrotic, and (vi) epithelioid. The mixed (spindle and epithelioid) type is largely the most common variant among the choroid melanomas. Spindle cell melanoma has the best prognosis. Epithelioid is most likely to spread, whilst mixed cell melanomas have an intermediate behaviour. Of note, the size and position of the tumour also affects the prognosis of individual melanomas. Uveal melanomas can invade locally within the eye, and form deposits in other organs, but most commonly the liver.
Treatment	Local resection, enucleation, photocoagulation, external beam irradiation, brachytherapy, and laser therapy (these techniques are all included in the following sentences but with a different sequence). The major aims of the actual therapeutic protocols for uveal melanoma are: (i) to prevent metastatic disease, (ii) to reduce disfiguring consequences, and (iii) to preserve ocular function. Conservative therapeutic procedures include brachytherapy, proton beam radiotherapy, stereotactic radiotherapy, transpupillary thermotherapy, trans-scleral local resection, transretinal resection and diode laser therapy. However, local resection and enucleation is still required in a significant proportion of patients.
Evolution	Metastasis occurs, mainly to the liver, with approximately half of patients treated with enucleation dying within ten to fifteen years; the highest rates of metastasis ocurr in the first five years, but have been recorded over forty years after the primary tumour was detected.
Prognosis	Despite recent progress in local therapy, the prognosis of patients with uveal melanoma have remained stable. 15-30% of treated patients died within 5 years following the diagnosis and initial therapy due to metastases, particularly in the liver. Disseminated disease is usually fatal within 1 year after the diagnosis. Spindle cell tumours, and those less than 10 mm in diameter have the best outcome. Ciliary body melanomas and those with extravascular matrix patterns and where there is scleral invasion have a worse prognosis. Other prognostic modifiers are emerging from cytogenetic and molecular studies (see below).

Cytogenetics

Cytogenetics Morphological

Most analysis have been performed on ciliary body and choroid melanomas, usually revealing relatively simple chromosome alterations, often with diploid karyotypes. The most common abnormality is loss of all or part of chromosome 3. Chromosome 3 monosomy is the major genetic factor of poor prognosis, as it is associated with a 70% rate of mortality within 4 years following tumor enucleation. This cytogenetic anomaly is also associated with other clinical and histological poor prognostic factors and, therefore, seems to represent a distinct pathologic entity. A significant proportion of uveal melanomas show gross abnormalities of one of the 2 copies of chromosome 6 (either duplication of 6p, or deletion of 6q). Trisomy of 6p appears to be mutually exclusive with chromosome 3 monosomy and links with a better prognosis. Conversely, 6q deletion occurs more commonly in metastasizing tumors. A further poor prognostic factor, strongly associated with metastatic death, is 8q trisomy (also in form of 8q isochrosome), which usually appears later in the natural history of uveal melanoma. Other less frequent chromosome abnormalities reported in uveal melanoma include 1p and 13q monosomy, as well as chromosome 21 trisomy.

Cytogenetics Molecular

Comparative genomic hybridization and spectral karyotyping studies mainly confirmed cytogenetic data and identified other minor chromosome abnormalities, such as alterations on 7q and 9p, which at the moment do not show a clear relationship with tumor formation, progression and prognosis. Loss of heterozygosity (LOH) analysis by microsatellite genotyping significantly increased the rate of detected chromosome imbalances, especially of chromosome 3, 6 and 8. This finding is explained by the fact that LOH studies detect not only monosomy/trisomy but also isodisomy. The actual rate of the major chromosome abnormalities in uveal melanoma, resulting from an integrated approach of standard cytogenetics, comparative genomic hybridization, spectral karyotyping and LOH studies by microsatellite analysis is: 50-60% for chromosome 3 monosomy, 40% for 8q trisomy, 25% for 6p trisomy, 25% for 6q monosomy, 17% for 1p monosomy and 15% for 13q monosomy. Fluorescent in-situ hybridization techniques are used to detect single gene or small chromosome region amplification (see below). Recently, an MLPA kit has been developed in order to quickly identify the more common chromosome abnormalities in uveal melanoma.

Genes involved and Proteins

Gene Name	TGFBR2 (Transforming growth factor-beta receptor, type 2)
Location	3p22
Note	LOH of the 3p22 chromosome region, in which maps TGFBR2, has been identified in 6 out of 19 uveal melanomas, and 61% of these tumors demonstrated perturbed TGFbeta pathway. At the moment, no mutation in genes encoding components of this pathways has been demonstrated in uveal melanoma. TGFbeta seems to upregulate levels of MMP-2 and, in particular, to increase adhesion of non-invasive uveal melanoma cell to hepatic ones. Therefore, it may contribute to the preferential targeting of the liver by uveal melanoma.

Gene Name	MDM2 (HDM2, Mouse double minute 2 homolog).
Location	12q14.3-q15
Note	More than 90% of the analyzed uveal melanomas show HDM2 overexpression. HDM2 is an inhibitor of p53. Thus, overexpression of HDM2 may partially inhibit p53 pathway in uveal melanoma and is associated to poor outcome.

Gene Name	CCND1 (Cyclin D1)
Location	11q13
Note	Cyclin D1 is overexpressed in nearly 40% of uveal melanoma. This protein activates CDK4, which is the Rb kinase. Therefore, overexpression of Cyclin D1 blocks the active repressor function of Rb on the cell cycle. Also Cyclin D1 overexpression seems to link to poor prognosis.

Gene Name	CDKN2A (Cyclin-dependent kinase inhibitor 2A)
Location	9p21
Note	Although CDKN2A mutations are extremely rare in uveal melanoma, LOH at the CDKN2A locus and CDKN2A promoter methylation occur in 24% and 6% of the analyzed tumors, respectively. A further study demonstrated that CDKN2A promoter methylation is more frequent and may occur up to 32% of the cases.

Gene Name	C-MYC
Location	8q24
Note	C-MYC is a protoncogene regulating cell proliferation, apoptosis and differentiation. Seventy to 90% uveal melanoma display overexpression of C-MYC. This finding associates to larger tumor size and improved survival. There are emerging evidences that C-MYC overexpression could be related to interferon resistance of the tumor. Recently, over expression of two other genes, namely DDFE1 and NBS1, mapping to 8q24 and 8q21, respectively, has been documented in uveal melanomas as a potential relevant consequence of 8q amplification.

Gene Name	BCL2 (B cell CLL/lymphoma 2)
Location	18q21.3
Note	The vast majority of uveal melanoma shows overexpression of BCL-2. This gene seems to be required for tumor cell survival and proliferation, as its inhibition leads to cell apoptosis.

To be noted

The molecular basis of tumor progression is recently emerging. It is hypothesized that the earliest event may be the underactivity of the Rb pathway, for example due to overexpression of Cyclin D or underexpression of CDKN2A. These features could determine the formation of a choroidal nevus. The switch to melanoma could be determined by the inhibition of the p53 pathway. Monosomy of the chromosome 3 determines the transformation in a more aggressive type of uveal melanoma with features of neoangiogenesis and local infiltration. Finally, 8q triplication, with the consequent overexpression of several protoncogenes, among others C-MYC, NBS1 and DDEF1, lead to metastasis formation.

External links

Other database	http://www.mlpa.com

Bibliography

Chromosomal analysis of colonic adenomatous polyps.

Longy M, Saura R, Schouler L, Mauhin C, Goussot JF, Grison O, Couzigou P

Cancer genetics and cytogenetics. 1990 ; 49 (2) : 249-257.

PMID 2208061

Nonrandom chromosomal abnormalities in primary uveal melanoma.

Prescher G, Bornfeld N, Becher R

Journal of the National Cancer Institute. 1990 ; 82 (22) : 1765-1769.

PMID 2231772

Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma.

Horsthemke B, Prescher G, Bornfeld N, Becher R

Genes, chromosomes & cancer. 1992 ; 4 (3) : 217-221.

PMID 1382562

C-myc oncogene expression in ocular melanomas.

Royds JA, Sharrard RM, Parsons MA, Lawry J, Rees R, Cottam D, Wagner B, Rennie IG

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 1992 ; 230 (4) : 366-371.

PMID 1505770

Cytogenetic analysis of posterior uveal melanoma.

Wiltshire RN, Elner VM, Dennis T, Vine AK, Trent JM

Cancer genetics and cytogenetics. 1993 ; 66 (1) : 47-53.

PMID 8467475

Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation.

Prescher G, Bornfeld N, Friedrichs W, Seeber S, Becher R

Cancer genetics and cytogenetics. 1995 ; 80 (1) : 40-46.

PMID 7697631

Comparative genomic hybridization analysis of archival formalin-fixed paraffin-embedded uveal melanomas.

Ghazvini S, Char DH, Kroll S, Waldman FM, Pinkel D

Cancer genetics and cytogenetics. 1996 ; 90 (2) : 95-101.

PMID 8830715

Expression of bcl-2 in uveal malignant melanoma.

Jay V, Yi Q, Hunter WS, Zielenska M

Archives of pathology & laboratory medicine. 1996 ; 120 (5) : 497-498.

PMID 8639055

Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis.

Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, Potter AM, Rees RC

Genes, chromosomes & cancer. 1997 ; 19 (1) : 22-28.

PMID 9135991

c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma.

Chana JS, Wilson GD, Cree IA, Alexander RA, Myatt N, Neale M, Foss AJ, Hungerford JL

The British journal of ophthalmology. 1999 ; 83 (1) : 110-114.

PMID 10209447

Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway.

Parrella P, Sidransky D, Merbs SL

Cancer research. 1999 ; 59 (13) : 3032-3037.

PMID 10397238

Deregulation of the Rb and p53 pathways in uveal melanoma.

Brantley MA Jr, Harbour JW

The American journal of pathology. 2000 ; 157 (6) : 1795-1801.

PMID 11106551

Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region.

Brantley MA Jr, Harbour JW

Cancer research. 2000 ; 60 (16) : 4320-4323.

PMID 10969768

The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma.

Coupland SE, Anastassiou G, Stang A, Schilling H, Anagnostopoulos I, Bornfeld N, Stein H

The Journal of pathology. 2000 ; 191 (2) : 120-126.

PMID 10861569

Abnormalities of the transforming growth factor-beta pathway in ocular melanoma.

Myatt N, Aristodemou P, Neale MH, Foss AJ, Hungerford JL, Bhattacharya S, A Cree I

The Journal of pathology. 2000 ; 192 (4) : 511-518.

PMID 11113869

Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma.

Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S

Investigative ophthalmology & visual science. 2001 ; 42 (2) : 313-317.

PMID 11157859

Detection of uveal melanoma by optometrists in the United Kingdom.

Damato B

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists). 2001 ; 21 (4) : 268-271.

PMID 11430620

Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization.

Parrella P, Caballero OL, Sidransky D, Merbs SL

Investigative ophthalmology & visual science. 2001 ; 42 (8) : 1679-1684.

PMID 11431428

Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma.

van der Velden PA, Metzelaar-Blok JA, Bergman W, Monique H, Hurks H, Frants RR, Gruis NA, Jager MJ

Cancer research. 2001 ; 61 (13) : 5303-5306.

PMID 11431374

Incidence of uveal melanoma in Sweden from 1960 to 1998.

Bergman L, Seregard S, Nilsson B, Ringborg U, Lundell G, Ragnarsson-Olding B

Investigative ophthalmology & visual science. 2002 ; 43 (8) : 2579-2583.

PMID 12147588

Transducible peptide therapy for uveal melanoma and retinoblastoma.

Harbour JW, Worley L, Ma D, Cohen M

Archives of ophthalmology. 2002 ; 120 (10) : 1341-1346.

PMID 12365913

Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma.

Hearle N, Damato BE, Humphreys J, Wixey J, Green H, Stone J, Easton DF, Houlston RS

Investigative ophthalmology & visual science. 2003 ; 44 (2) : 458-462.

PMID 12556369

Role of MC1R variants in uveal melanoma.

Hearle N, Humphreys J, Damato BE, Wort R, Talaban R, Wixey J, Green H, Easton DF, Houlston RS

British journal of cancer. 2003 ; 89 (10) : 1961-1965.

PMID 14612910

Molecular genetics of uveal melanoma.

Loercher AE, Harbour JW

Current eye research. 2003 ; 27 (2) : 69-74.

PMID 14632157

Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival.

Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK

Investigative ophthalmology & visual science. 2003 ; 44 (3) : 1008-1011.

PMID 12601021

Incidence of uveal melanoma in the United States: 1973-1997.

Singh AD, Topham A

Ophthalmology. 2003 ; 110 (5) : 956-961.

PMID 12750097

Developments in the management of uveal melanoma.

Damato B

Clinical & experimental ophthalmology. 2004 ; 32 (6) : 639-647.

PMID 15575836

Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death.

Onken MD, Worley LA, Ehlers JP, Harbour JW

Cancer research. 2004 ; 64 (20) : 7205-7209.

PMID 15492234

Sunlight exposure and pathogenesis of uveal melanoma.

Singh AD, Rennie IG, Seregard S, Giblin M, McKenzie J

Survey of ophthalmology. 2004 ; 49 (4) : 419-428.

PMID 15231397

The relation between c-myc expression and interferon sensitivity in uveal melanoma.

Tulley PN, Neale M, Jackson D, Chana JS, Grover R, Cree I, Grobbelaar AO, Wilson GD

The British journal of ophthalmology. 2004 ; 88 (12) : 1563-1567.

PMID 15548813

Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: current views and new therapeutic prospects.

Baggetto LG, Gambrelle J, Dayan G, Labialle S, Barakat S, Michaud M, Grange JD, Gayet L

Cancer treatment reviews. 2005 ; 31 (5) : 361-379.

PMID 15994016

NBS1 expression as a prognostic marker in uveal melanoma.

Ehlers JP, Harbour JW

Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 ; 11 (5) : 1849-1853.

PMID 15756009

DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma.

Ehlers JP, Worley L, Onken MD, Harbour JW

Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 ; 11 (10) : 3609-3613.

PMID 15897555

A potential role for TGFbeta in the regulation of uveal melanoma adhesive interactions with the hepatic endothelium.

Woodward JK, Rennie IG, Burn JL, Sisley K

Investigative ophthalmology & visual science. 2005 ; 46 (10) : 3473-3477.

PMID 16186321

Progressive enlargement of cavity within melanoma masquerading as iris cyst.

Criss JS, Shields CL, Materin MA, Reichel E, Eagle RC Jr, Shields JA

Cornea. 2006 ; 25 (7) : 863-865.

PMID 17068469

Treatment of primary intraocular melanoma.

Damato B

Expert review of anticancer therapy. 2006 ; 6 (4) : 493-506.

PMID 16613538

Molecular pathobiology of uveal melanoma.

Ehlers JP, Harbour JW

International ophthalmology clinics. 2006 ; 46 (1) : 167-180.

PMID 16365562

REVIEW articles	automatic search in PubMed
Last year publications	automatic se arch in PubMed

Contributor(s)

Written	06-1999	Karen Sisley
		The Institute for Cancer Studies, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK
Updated	04-2007	Marco Castori, Paola Grammatico
		The Institute for Cancer Studies, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK

Citation

This paper should be referenced as such :

Sisley K . Head and neck: Posterior uveal melanoma. Atlas Genet Cytogenet Oncol Haematol. June 1999 . URL : http://AtlasGeneticsOncology.org/Tumors/UvealmelanomID5047.html

Castori M, Grammatico P . Head and neck: Posterior uveal melanoma. Atlas Genet Cytogenet Oncol Haematol. April 2007 . URL : http://AtlasGeneticsOncology.org/Tumors/UvealmelanomID5047.html

This paper is referenced by INIST as such :

http://documents.irevues.inist.fr/bitstream/2042/37545/1/06-1999-UvealmelanomID5047.pdf   [ Bibliographic record ]

http://documents.irevues.inist.fr/bitstream/handle/2042/16968/04-2007-UvealmelanomID5047.pdf   [ Bibliographic record ]

© Atlas of Genetics and Cytogenetics in Oncology and Haematology

indexed on : Sat Mar 9 12:39:40 CET 2013

For comments and suggestions or contributions, please contact us